|
MechanismLipid modulators |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date18 May 2023 |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date29 Apr 2022 |
|
MechanismCYP17A1 inhibitors |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date28 Apr 2011 |
评价HRS-5965片治疗阵发性睡眠性血红蛋白尿患者的长期安全性和有效性的多中心、开放研究
[Translation] A multicenter, open-label study to evaluate the long-term safety and efficacy of HRS-5965 tablets in the treatment of patients with paroxysmal nocturnal hemoglobinuria
评价HRS-5965治疗阵发性睡眠性血红蛋白尿(PNH)患者的长期安全性、耐受性、有效性
[Translation] To evaluate the long-term safety, tolerability, and effectiveness of HRS-5965 in the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH)
An Open Label, Multicenter Study to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria
This is a multicenter, single-arm, open-label study. Patients with Paroxysmal Nocturnal Hemoglobinuria who had previously received and completed the HRS-5965 study well included. All eligible subjects received HRS-5965 tablets until the end of treatment in this study.
A Trial to Evaluate the Efficacy and Safety of HRS-5965 Tablets in Primary IgA Nephropathy
The study is being conducted to evaluate the efficacy, and safety of HRS-5965 tablets for primary IgA nephropathy. To explore the effective dosage of HRS-5965 tablets for primary IgA nephropathy.
100 Clinical Results associated with Chengdu Suncadia Pharmaceuticals Co., Ltd.
0 Patents (Medical) associated with Chengdu Suncadia Pharmaceuticals Co., Ltd.
100 Deals associated with Chengdu Suncadia Pharmaceuticals Co., Ltd.
100 Translational Medicine associated with Chengdu Suncadia Pharmaceuticals Co., Ltd.